Orca Bio Strengthens Leadership Team in Preparation for Commercial Launch of Innovative Cell Therapy

Orca Bio, a late-stage biotechnology company, has taken a decisive step towards the commercialization of its lead investigational allogeneic T-cell immunotherapy, Orca-T, with the appointment of Steve Gavel as Chief Commercial Officer and Allison Frisbee as Senior Vice President, Legal. These strategic hires underscore the company's commitment to transforming the therapeutic landscape for patients with high-risk blood cancers, including acute myeloid leukemia and myelodysplastic syndrome.

Steve Gavel brings over 30 years of experience in the biotechnology and pharmaceutical sectors, with a focus on the commercialization of cell and gene therapies. His expertise is expected to be invaluable as Orca Bio prepares for the potential launch of Orca-T. Gavel's previous role at Legend Biotech, where he led the global commercial development efforts for CAR-T therapies, highlights his capability to navigate the complexities of bringing innovative treatments to market.

Allison Frisbee's appointment further strengthens Orca Bio's leadership team. With her extensive experience in legal and regulatory challenges within the life science industry, Frisbee is poised to contribute significantly to the company's strategic direction. Her background in overseeing legal, HR, and compliance functions at Kronos Bio, Jazz Pharmaceuticals, and Bristol Myers Squibb will be crucial as Orca Bio advances its mission.

The implications of these appointments extend beyond Orca Bio, signaling a potential shift in the treatment paradigms for blood cancers. The company's high-precision cell therapy platform represents a novel approach to treating these diseases, offering hope to patients with limited options. As Orca Bio moves closer to the commercial launch of Orca-T, the industry watches closely, anticipating the impact of this innovative therapy on patient outcomes and the broader field of cell therapy.